ABSTRACT
Cardiovascular drug development has been altered considerably during the past 18 years, the period during which the symposium series has been in existence. Changes have affected drug discovery, trial design, endpoints requiring investigation, consideration of drug interactions and relative emphasis on economic concomitants of therapy. These changes, all still occurring, define and circumscribe the foreseeable future of cardiovascular drug development.
